<DOC>
	<DOCNO>NCT00035620</DOCNO>
	<brief_summary>Physicians conduct clinical trial patient pediatric sarcoma . Sarcoma type bone cancer treat chemotherapy affect bone marrow , blood cell produce . Neutrophils type white blood cell fight infection produce bone marrow . If neutrophil count becomes low due chemotherapy , potentially serious condition call neutropenia occurs . Neutropenia serious affect body 's ability protect many type infection . Pegfilgrastim investigational drug evaluate potential ability increase number neutrophil . The purpose study determine safety effectiveness pegfilgrastim prevent neutropenia follow chemotherapy pediatric patient age 21 sarcoma .</brief_summary>
	<brief_title>Pegfilgrastim Support Pediatric Sarcoma Patients Receiving Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Sarcoma * No previous chemotherapy radiotherapy * Patients receive chemotherapy consist Vincristine , Doxorubicin , Cyclophosphamide , Etoposide , Ifosfamide , Mesna</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Bone cancer</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Neutropenia</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>